

SCHEDULING STATUS

S4

DUMIVA DISPERSIBLE TABLETS, 120mg/60 mg

Abacavir/Lamivudine

Read all of this leaflet carefully before your child starts taking DUMIVA

DISPERSIBLE TABLETS

- Keep this leaflet. You may need to read it again.
- If you have further questions, please ask your doctor, pharmacist, nurse or other health care provider.
- DUMIVA DISPERSIBLE TABLETS have been prescribed for your child personally and you should not share your medicine with other people. It may harm them, even if their symptoms are the same as yours.

1.3.2.1 Clean Patient Information Leaflet

HYPERSENSITIVITY REACTION

Patients taking DUMIVA DISPERSIBLE TABLETS which contain abacavir and lamivudine may develop a hypersensitivity reaction (serious allergic reaction) which can be life-threatening and can cause death, if treatment with DUMIVA DISPERSIBLE TABLETS is continued. It is essential that you read the information on this reaction in this leaflet under the heading “**Take special care with DUMIVA DISPERSIBLE TABLETS**”. There is also an alert card included in the DUMIVA DISPERSIBLE TABLETS pack to remind you and medical staff about DUMIVA DISPERSIBLE TABLETS’s hypersensitivity. This card should be removed from the pack and kept with you/the patient at all times. The text on this card is shown below.

CONTACT YOUR DOCTOR IMMEDIATELY for advice on whether you or the patient should stop taking DUMIVA DISPERSIBLE TABLETS if:

- 1) He/she gets a skin rash OR**
- 2) He/she gets one or more symptoms from at least TWO of the following groups:**
 - fever
 - shortness of breath, sore throat or cough
 - nausea or vomiting or diarrhoea or abdominal pain
 - severe tiredness or achiness or generally feeling ill

If your child discontinued DUMIVA DISPERSIBLE TABLETS due to a hypersensitivity reaction **HE/SHE MUST NEVER TAKE** it again, or any other medicine containing abacavir, as **within hours** your child may experience a life- threatening lowering of their blood pressure or death.

What is in this leaflet

1. What DUMIVA DISPERSIBLE TABLETS are and what they are used for.
2. What you need to know before you give DUMIVA DISPERSIBLE

1.3.2.1 Clean Patient Information Leaflet

TABLETS.

3. How to give DUMIVA DISPERSIBLE TABLETS.
4. Possible side effects.
5. How to store DUMIVA DISPERSIBLE TABLETS.
6. Contents of the pack and other information.

1. What DUMIVA DISPERSIBLE TABLETS are and what they are used for

What DUMIVA DISPERSIBLE TABLETS are:

DUMIVA DISPERSIBLE TABLETS belong to a group of antiviral medicines, also known as antiretrovirals, called nucleoside analogue reverse transcriptase inhibitors (NRTIs).

What they are used for:

These are used to treat Human Immunodeficiency Virus (HIV) infection. DUMIVA DISPERSIBLE TABLETS are used in combination with other antiretroviral medicines for the treatment of HIV infection. DUMIVA DISPERSIBLE TABLETS are always used with other anti-HIV-1 medicines.

DUMIVA DISPERSIBLE TABLETS may improve your child's condition, but they are not a cure for the HIV infection. HIV infection is a disease spread by contact with blood or sexual contact with an infected individual. Treatment with DUMIVA DISPERSIBLE TABLETS has not been shown to eliminate the risk of passing HIV infection on to others by sexual contact or by blood transfer. Therefore, you/your child must continue to take appropriate precautions to avoid giving the virus to others.

This product is intended for use in children. Safety information on its use in adults is also provided.

2. What you need to know before you take DUMIVA

DISPERSIBLE TABLETS

Do not take DUMIVA DISPERSIBLE TABLETS:

- If your child previously suffered an allergic reaction to any of the active ingredients, abacavir or lamivudine, or any other ingredient of DUMIVA DISPERSIBLE TABLETS (listed in section 6).
- If your child has liver disease.
- If your child has kidney disease.
- If your child is taking emtricitabine (a medicine to treat HIV infection).
- If he/she has phenylketonuria.
- If she is pregnant or breastfeeding her baby (see 'Pregnancy, breastfeeding and fertility').

Warnings and precautions

Before giving DUMIVA DISPERSIBLE TABLETS, tell your child's doctor about all of your child's medical conditions, including if:

- your child has been tested and know whether or not he/she has a particular gene variation called HLA-B*5701;
- your child has heart problems, smoke or suffer from diseases that increase his/her risk of heart disease e.g. high blood pressure, high cholesterol or diabetes.

If you are not sure about any of these, please consult your child's doctor.

Take special care with DUMIVA DISPERSIBLE TABLETS:

Hypersensitivity reaction (serious allergic reaction):

1.3.2.1 Clean Patient Information Leaflet

The most important symptoms of this reaction are high temperature (fever) and skin rash. Other frequently seen signs or symptoms are nausea, vomiting, diarrhoea, abdominal pain, shortness of breath, cough, headache, and severe tiredness. Other symptoms may be joint or muscle pain, swelling of the neck and sore throat. Occasionally swelling of the eye, ulcers in the mouth or low blood pressure may occur. The symptoms of this allergic reaction can occur at any time during treatment with DUMIVA DISPERSIBLE TABLETS. However, they usually occur in the first six weeks of treatment and get worse with continued treatment. If you are caring for a child who is being treated with DUMIVA DISPERSIBLE TABLETS it is important you understand the information about this hypersensitivity reaction. If your child gets the symptoms described below, it is essential you follow the instructions given.

The hypersensitivity reaction can be life-threatening or fatal if treatment with DUMIVA DISPERSIBLE TABLETS is continued.

You should contact your doctor immediately for advice on whether you should stop taking/giving DUMIVA DISPERSIBLE TABLETS if:

you/the patient get(s) skin rash OR

you/the patient get(s) one or more symptoms from at least TWO of the

following groups:

- fever
- shortness of breath, sore throat or cough

1.3.2.1 Clean Patient Information Leaflet

1 – nausea or vomiting or diarrhoea or abdominal pain

2 – severe tiredness or achiness or general ill-feeling

3 If your child discontinued DUMIVA DISPERSIBLE TABLETS because of a
4 hypersensitivity reaction **HE/SHE MUST NEVER TAKE DUMIVA DISPERSIBLE**

5 **TABLETS** or any other medicine containing abacavir again as within hours he/she
6 may experience a life-threatening lowering of his/her blood pressure or death.

7 Occasionally life-threatening hypersensitivity reactions have occurred when DUMIVA
8 DISPERSIBLE TABLETS were restarted in patients who got only one of the
9 symptoms on the alert card before stopping.

10 If your child is hypersensitive to DUMIVA DISPERSIBLE TABLETS, you should
11 return all unused tablets to the doctor or pharmacist for proper disposal.

12
13 DUMIVA DISPERSIBLE TABLETS can cause a condition called lactic acidosis,
14 together with an enlarged liver. This rare but serious side effect occurs more often in
15 women. If you/the patient have(s) liver disease you/they may also be more at risk of
16 getting this condition while you/they are being treated with DUMIVA DISPERSIBLE
17 TABLETS. The doctor will monitor you/the patient for any signs that you/they may be
18 developing lactic acidosis.

- 19 • If your child has ever had liver disease, including hepatitis B or C (if he/she
20 has hepatitis B infection, do not stop giving DUMIVA DISPERSIBLE
21 TABLETS without a doctor's advice, as the hepatitis may come back).
- 22 • If your child is very overweight (especially if your child is a girl).
- 23 • Your child's body shape may change. If your child is taking combination
24 antiretroviral therapy for HIV, he/she may find that his/her body shape
25 changes, because of changes in fat distribution.

1.3.2.1 Clean Patient Information Leaflet

26 • You must contact your doctor if your child experiences joint aches and pain,
27 ○ joint stiffness or difficulty in movement.

28 • DUMIVA DISPERSIBLE TABLETS help to control your child's condition
29 but is not a cure for HIV infection. Your child will need to take it every day.
30 Do not stop giving DUMIVA DISPERSIBLE TABLETS without first talking
31 to your child's doctor. If you are concerned that your child may be
32 developing symptoms of a hypersensitivity reaction (see above), call the
33 doctor immediately who will advise you whether you need to stop giving
34 DUMIVA DISPERSIBLE TABLETS.

35 Your child may continue to develop other infections and other illnesses
36 associated with HIV disease. You should therefore keep in regular
37 contact with your child's doctor while giving DUMIVA DISPERSIBLE
38 TABLETS.

39 Treatment with DUMIVA DISPERSIBLE TABLETS has not been shown to decrease
40 the risk of passing HIV infection on to others by sexual contact or by blood transfer.
41 Your child should continue to use appropriate precautions to prevent this.

42

43 To protect other people from becoming infected with HIV:

- 44 • your child must use a condom when he has oral or penetrative sex;
- 45 • your child must not risk blood transfer – for example, do not share
46 needles.

47

48 **Risk of cardiovascular events**

- 49 • It cannot be excluded that abacavir may increase the risk of having cardiovascular
50 events.

1.3.2.1 Clean Patient Information Leaflet

- 51 • Tell your doctor if you have cardiovascular problems, if you smoke, or have other
52 illnesses that may increase your risk of cardiovascular diseases such as high blood
53 pressure, or diabetes. Do not stop taking DUMIVA DISPERSIBLE TABLETS unless
54 your doctor advises you to do so.

55

56 **Children and adolescents**

57 Do not give DUMIVA DISPERSIBLE TABLETS to children younger than 3 months and
58 weighing more than 25 kg.

59

60 **Other medicines and DUMIVA DISPERSIBLE TABLETS**

61 Always tell your health care provider if you are taking any other medicine. (This
62 includes all complementary or traditional medicines.)

63 Do not take DUMIVA DISPERSIBLE TABLETS if you are already taking any of the
64 following medicines:

- 65 • Emtricitabine (other antiretroviral medicine). See 'Do not take DUMIVA
66 DISPERSIBLE TABLETS'.

67

68 It is important to tell your child's doctor about all the medicines that he/she is taking or
69 has taken, including those you have bought. Especially tell your child's doctor if your
70 child is taking any of the following medicines:

- 71 • Ricampicin (used to treat TB).
72 • Phenobarbital (used to treat epilepsy).
73 • Phenytoin (used to treat epilepsy).
74 • Methadone (medicine used to prevent withdrawal symptoms in people who
75 are addicted to opioid substances such as heroin).

1.3.2.1 Clean Patient Information Leaflet

- 76 • Trimethoprim + sulfamethoxazole (co-trimoxazole) (two antibiotics which
77 can also be given together to treat some types of infections).
- 78 • Ganciclovir (antiviral medicine used to treat infections caused by a virus
79 called cytomegalovirus).
- 80 • Foscarnet (belongs to a group of medicines called anti-viral medicines).
- 81 • Zalcitabine (used in combination with other medicines for HIV infection).
- 82 • Other medicines containing lamivudine, used to treat HIV infection or hepatitis B
83 infection.
- 84 • Cladribine, used to treat hairy cell leukaemia.
- 85 • Alcohol.
- 86 • Oral vitamin A related medicines, e.g. isotretinoin (for acne therapy).
- 87 • Ribavirin, for treating hepatitis C. Abacavir may make the combination of ribavirin
88 and pegylated interferon less effective at reducing levels of hepatitis C virus in the
89 body.

90

91 **DUMIVA DISPERSIBLE TABLETS with food and drink:**

92 DUMIVA DISPERSIBLE TABLETS can be taken with or without food.

93

94 **Pregnancy, breastfeeding and fertility**

95 You should not be treated with DUMIVA DISPERSIBLE TABLETS if you are
96 pregnant or planning to become pregnant as the safe use of DUMIVA DISPERSIBLE
97 TABLETS in human pregnancy has not been established. The doctor will advise
98 whether your child should continue to take DUMIVA DISPERSIBLE TABLETS.

99

100

1.3.2.1 Clean Patient Information Leaflet

101 **Breastfeeding:**

102 After receiving DUMIVA DISPERSIBLE TABLETS it is likely to be found in human
103 breast milk. Your child is therefore advised not to breastfeed while receiving DUMIVA
104 DISPERSIBLE TABLETS.

105
106 If your child is pregnant or breastfeeding, think your child may be pregnant or are
107 planning to have a baby, please consult your child's doctor, pharmacist or other
108 health care provider for advice before your child starts taking this medicine.

109

110 **Driving and using machines**

111 DUMIVA DISPERSIBLE TABLETS are intended for children from 3 months to 12
112 years. DUMIVA DISPERSIBLE TABLETS is unlikely to affect a patient's ability to
113 operate machinery or drive.

114 Patients must not operate machines or drive unless they are feeling well. If
115 there are any concerns, tell the doctor.

116

117 **Important information about some of the ingredients of DUMIVA**

118 **DISPERSIBLE TABLETS:**

119 DUMIVA DISPERSIBLE TABLETS contain aspartame which is a source of
120 phenylalanine. This may be harmful for people with phenylketonuria.

121

122 **3. How to give DUMIVA DISPERSIBLE TABLETS**

- 123 • Do not share medicines prescribed for you with any other person.
- 124 • Always give DUMIVA DISPERSIBLE TABLETS exactly as your
125 doctor has told you.

1.3.2.1 Clean Patient Information Leaflet

- 126
- Check with your doctor or pharmacist if you are not sure.
- 127
- Treatment should be prescribed and started by a medical doctor experienced in
- 128
- the management of HIV infection.

129

130 **Children between 3 months and 12 years of age:**

- 131
- The recommended dose of DUMIVA DISPERSIBLE TABLETS for children is
- 132
- based on the child's body weight and will be determined by the doctor.
- 133
- The doctor will also explain how and when the tablets must be taken.

134

135 Your doctor will tell you how long your child's treatment with DUMIVA DISPERSIBLE
136 TABLETS will last. Do not stop treatment early.

137 If you have the impression that the effect of DUMIVA DISPERSIBLE TABLETS is too
138 strong or too weak, talk to the doctor or pharmacist.

139

140 **If you give more DUMIVA DISPERSIBLE TABLETS than you should:**

141 If you accidentally give the child too many DUMIVA DISPERSIBLE TABLETS
142 contact the nearest hospital emergency department for further advice.

143 In the event of overdose, speak to a doctor or pharmacist. If neither is available,
144 contact the nearest hospital or poison control centre for help.

145

146 **If you forget to give your child DUMIVA DISPERSIBLE TABLETS:**

147 If you forget to give a dose of DUMIVA DISPERSIBLE TABLETS, give it as soon as
148 you remember and then continue as before.

149 Do not give a double dose to make up for missed individual doses.

150

1.3.2.1 Clean Patient Information Leaflet

151 **Effects when treatment with DUMIVA DISPERSIBLE TABLETS is stopped:**

152 If you have stopped giving DUMIVA DISPERSIBLE TABLETS for any reason,
153 especially if you think your child is having side effects, or for any other illness, it is
154 important that you contact your child's doctor before restarting.

155 In some cases, the doctor will ask you to restart DUMIVA DISPERSIBLE TABLETS
156 under direct medical supervision or where medical care can be easily accessed by
157 yourself or others. If the doctor thinks that there is a possibility that your child's
158 symptoms are related to a hypersensitivity reaction, you may be told never to give
159 DUMIVA DISPERSIBLE TABLETS or any other medicine containing abacavir again.

160

161 **4. Possible side effects**

162 DUMIVA DISPERSIBLE TABLETS can have side effects.

163 Not all side effects reported for DUMIVA DISPERSIBLE TABLETS are
164 included in this leaflet. Should your general health worsen or if you
165 experience any untoward effects while taking DUMIVA DISPERSIBLE
166 TABLETS, please consult your health care provider for advice.

167

168 **If any of the following happens, stop taking DUMIVA DISPERSIBLE**
169 **TABLETS and tell your doctor immediately or go to the casualty**
170 **department at your nearest hospital:**

- 171 • swelling of the hands, feet, ankles, face, lips, mouth or throat, which
172 may cause difficulty in swallowing or breathing,
- 173 • rash or itching,
- 174 • fainting,
- 175 • widespread rash with blisters and peeling skin, particularly around the mouth,

1.3.2.1 Clean Patient Information Leaflet

176 nose, eyes and genitals (Stevens-Johnson syndrome) and a more
177 severe form causing skin peeling in more than 30 % of the body surface
178 (toxic epidermal necrolysis).

179
180 Some patients treated with DUMIVA DISPERSIBLE TABLETS and do not have a
181 gene called HLA-B*5701 developed a serious allergic reaction.

182 The hypersensitivity reaction can be life-threatening or fatal if treatment with
183 DUMIVA DISPERSIBLE TABLETS is continued. **You should contact your child's**
184 **doctor immediately for advice on whether you should stop giving him/her**

185 **DUMIVA DISPERSIBLE TABLETS if:**

- 186 • **Your child get(s) a skin rash OR**
- 187 • **Your child gets one or more symptoms from at least TWO of the following**
188 **groups:**

- 189 – fever
- 190 – shortness of breath, sore throat or cough
- 191 – nausea or vomiting or diarrhoea or abdominal (stomach) pain
- 192 – severe tiredness or aches and pains or generally feeling ill

193 These are all very serious side effects. If you or your child have them, you
194 may have had a serious reaction DUMIVA DISPERSIBLE TABLETS.

195 You may need urgent medical attention or hospitalisation.

196
197 **Tell your doctor immediately or go to the casualty department at your**
198 **nearest hospital if you notice any of the following:**

- 199 • swelling of the eye,
- 200 • mouth ulcers,

1.3.2.1 Clean Patient Information Leaflet

- 201 • low blood pressure,
- 202 • headache,
- 203 • lactic acidosis (is more likely to develop in people who have liver disease
- 204 • or in very overweight people, especially girls). It can be life-threatening, causing
- 205 failure of internal organs,
- 206 • liver disorders, such as jaundice, enlarged liver or fatty liver, hepatitis,
- 207 • inflammation of the pancreas (pancreatitis).

208 These are all serious side effects. You may need urgent medical attention.

209

210 **Tell your doctor if you notice any of the following:**

211 Frequent side effects:

- 212 • loss of appetite (anorexia),
- 213 • skin rash,
- 214 • difficulty in sleeping,
- 215 • cough,
- 216 • irritated or runny nose,
- 217 • hair loss,
- 218 • joint pains,
- 219 • muscle pain and discomfort.

220

221 Less frequent side effects:

- 222 • a low red blood cell count (anaemia) or low white blood cell count (neutropenia),
- 223 • redistribution/accumulation of body fat (fat may be lost from the legs, arms or
- 224 face; extra fat may build up around the tummy or on the breasts; fatty lumps

1.3.2.1 Clean Patient Information Leaflet

225 (sometimes called “buffalo hump”) may appear on the back of the neck),

226 • sensation of weakness in the limbs,

227 • increase in an enzyme called amylase,

228 • breakdown of muscle tissue.

229 If you notice any side effects not mentioned in this leaflet, please inform your

230 doctor or pharmacist.

231

232 **Reporting of side effects**

233 If you get side effects, talk to your doctor, pharmacist or nurse.

234 You can also report side effects to SAHPRA via the “6.04 Adverse Drug

235 Reaction Reporting Form”, found online under SAHPRA’s publications:

236 <https://www.sahpra.org.za/Publications/Index/8>. _

237 By reporting side effects, you can help provide more information on

238 the safety of DUMIVA DISPERSIBLE TABLETS.

239

240 **5. How to store DUMIVA DISPERSIBLE TABLETS**

241 Store all medicines out of reach of children.

242 Store at or below 30 °C.

243 Protect from light.

244 Store the tablets in the original container.

245 Keep the container tightly closed.

246 Do not use after the expiry date stated on the label.

247 Do not store in the bathroom.

248 Return all unused medicine to your pharmacist.

249 Do not dispose of unused medicine in drains or sewerage systems (e.g. toilets).

1.3.2.1 Clean Patient Information Leaflet

250

251 **6. Contents of the pack and other information**

252 **What DUMIVA DISPERSIBLE TABLETS contains:**

253 The active substances are lamivudine and abacavir in one dispersible tablet.

254 The other ingredients DUMIVA DISPERSIBLE TABLETS are:

255 The other ingredients are croscarmellose sodium, magnesium
256 stearate, microcrystalline cellulose {strawberry flavour: artificial
257 flavours, benzyl alcohol, maltodextrin, propylene glycol, triethyl
258 citrate}.

259 Contains aspartame.

260

261 **What DUMIVA DISPERSIBLE TABLETS looks like and contents of the**
262 **pack:**

263 **What DUMIVA DISPERSIBLE TABLETS looks like:**

264 White to off-white, round, biconvex tablet with a criss-cross score on both sides of the
265 tablet and debossed with M on the top left of the score over A on the bottom left of
266 the score and L on the bottom right of the score on one side of the tablet.

267 DUMIVA DISPERSIBLE TABLETS are presented in the following:

268 **Contents of the pack:**

269 High Density Polyethylene (HDPE) bottle pack (marketable pack) comprising of a
270 white opaque HDPE bottle with absorbent cotton and white opaque polypropylene
271 (PP) screw cap with a package insert in an outer carton.

272 Pack size of 28's, 30's and 60's.

273

274 Not all pack sizes are marketed.

1.3.2.1 Clean Patient Information Leaflet

275

276 **Holder of Certificate of Registration**

277 Viatris Healthcare (Pty) Ltd 4

278 Brewery Street

279 Isando Johannesburg,

280 1609

281

282 **This leaflet was last revised in**

283 Date of publication: February 2021

284 Date of revision of text: 17 October 2024

285

286 **Registration number**

287 49/20.2.8/0462

288

289 **Access to the corresponding Professional Information**

290 Can be obtained on the SAHPRA website.

291